Conformis (NSDQ:CFMS) posted third-quarter results today that missed the consensus forecast on Wall Street.

The Billerica, Massachusetts-based orthopedic medical device company reported a net loss of $13.0 million, or -$0.07 per share, on sales of $14.3 million for the three months ended Sept. 30. The third-quarter net loss grew 110% compared to Q3 2020, while sales declined 12% in that same time.

The results fell short of Wall Street’s expectations, where analysts were looking for a net loss per share of $0.06 on sales of $14.6 million.

“As COVID-19’s Delta variant became more pronounced during the quarter, the impact on elective procedures and our business was greater than expected,” Conformis President and CEO Mark Augusti said in a news release. “This resulted in a number of deferred procedures, many of which have already been rescheduled. The disruption caused by the Delta variant has had minimal effect on the limited market releases of our new Identity Imprint knee offering and our manufacturing partnership with Stryker. Both are progressing and we are positioned to capitalize on the shift in procedures to the ASC in 2022 and beyond.”

Conformis said it expects sales of $15.0 million to $17.0 million in the fourth quarter, providing a larger-than-usual range “due to the unpredictable recovery from the Delta variant and its potential impact on our existing scheduled fourth-quarter surgeries.”

Investors reacted by sending CFMS shares down more than 15% to $1.09 in after-hours trading.